Summary: The branch of medicine concerned with the application of NANOTECHNOLOGY to the prevention and treatment of disease. It involves the monitoring, repair, construction, and control of human biological systems at the molecular level, using engineered nanodevices and NANOSTRUCTURES. (From Freitas Jr., Nanomedicine, vol 1, 1999).

Top Publications

  1. Rizzo L, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013;24:1159-66 pubmed publisher
    In recent years, the use of nanomedicine formulations for therapeutic and diagnostic applications has increased exponentially...
  2. Tzeng S, Green J. Therapeutic nanomedicine for brain cancer. Ther Deliv. 2013;4:687-704 pubmed publisher
    ..b>Nanomedicine approaches have been developed in the laboratory, with some technologies being translated to the clinic, in ..
  3. Thorley A, Tetley T. New perspectives in nanomedicine. Pharmacol Ther. 2013;140:176-85 pubmed publisher
    ..One of the most exciting areas of development is that of nanomedicine. Due to their size (less than 100nm in one aspect), nanoparticles exhibit properties that are unlike that of ..
  4. Pritz C, Dudas J, Rask Andersen H, Schrott Fischer A, Glueckert R. Nanomedicine strategies for drug delivery to the ear. Nanomedicine (Lond). 2013;8:1155-72 pubmed publisher
    ..These novel peptide-mediated strategies for specific delivery are reviewed in this article. Finally, the biosafety of these vector systems is still an outstanding issue, since long-term application to the ear has not yet been assessed. ..
  5. Bertalan F, László B, Attila V. [Targeted nanomedicine in diagnostics and therapy of neurological diseases]. Ideggyogy Sz. 2013;66:155-63 pubmed
    ..The nanomedicine now, --and likely more in the future--opens a new horizon in the treatment of neurological diseases...
  6. Yang Z, Kang S, Zhou R. Nanomedicine: de novo design of nanodrugs. Nanoscale. 2014;6:663-77 pubmed publisher
    ..These studies may shed light on a better understanding of the molecular mechanisms behind these nanodrugs, and also provide new insights and direction for the future design of nanomedicines. ..
  7. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine. 2013;8:899-908 pubmed publisher
    ..In this review, we highlight the mechanisms of drug resistance and the novel strategies using nanoscale drugs to eliminate CSCs. ..
  8. Camp E, Wang C, Little E, Watson P, Pirollo K, Rait A, et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013;20:222-8 pubmed publisher
    ..This approach has the potential to be translated into a new, more effective therapy for pancreatic cancer. Further optimization is ongoing, moving towards a Phase 1B/2 clinical trial. ..
  9. Castronovo M, Stopar A, Coral L, Redhu S, Vidonis M, Kumar V, et al. Effects of nanoscale confinement on the functionality of nucleic acids: implications for nanomedicine. Curr Med Chem. 2013;20:3539-57 pubmed
    ..that nucleic acids function in a qualitatively different manner within nanostructured systems, and suggest that these novel properties, if better understood, will enable the development of powerful molecular tools for nanomedicine.

More Information


  1. Iyer A, Singh A, Ganta S, Amiji M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65:1784-802 pubmed publisher
    ..Illustrative examples of nanoparticles engineered for drug/gene combination delivery and stimuli responsive nanoparticle systems for cancer therapy are also discussed. ..
  2. Zarbin M, Arlow T, Ritch R. Regenerative nanomedicine for vision restoration. Mayo Clin Proc. 2013;88:1480-90 pubmed publisher
    ..Nanotechnology will play an important role in early- and late-stage interventions in the management of blinding diseases. ..
  3. Kaddi C, Phan J, Wang M. Computational nanomedicine: modeling of nanoparticle-mediated hyperthermal cancer therapy. Nanomedicine (Lond). 2013;8:1323-33 pubmed publisher
    Nanoparticle-mediated hyperthermia for cancer therapy is a growing area of cancer nanomedicine because of the potential for localized and targeted destruction of cancer cells...
  4. Bala V, Rao S, Boyd B, Prestidge C. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release. 2013;172:48-61 pubmed publisher
    ..More recently, macromolecular prodrugs (i.e. EZN-2208, IMMU-130) and nanomedicine formulations (i.e...
  5. Tan S, Li X, Guo Y, Zhang Z. Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale. 2013;5:860-72 pubmed publisher
    Recent advances in nanotechnology and material sciences have promoted the development of nanomedicine. Among the formulations developed, novel lipid-enveloped hybrid nanoparticles have attracted more attention because of their special ..
  6. Das S, Dowding J, Klump K, McGinnis J, Self W, Seal S. Cerium oxide nanoparticles: applications and prospects in nanomedicine. Nanomedicine (Lond). 2013;8:1483-508 pubmed publisher
    ..CNPs are well tolerated in both in vitro and in vivo biological models, which makes CNPs well suited for applications in nanobiology and regenerative medicine. ..
  7. Shah V, Taratula O, Garbuzenko O, Taratula O, Rodriguez Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013;19:6193-204 pubmed publisher
    ..Clin Cancer Res; 19(22); 6193-204. ©2013 AACR. ..
  8. Prabhakar U, Maeda H, Jain R, Sevick Muraca E, Zamboni W, Farokhzad O, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412-7 pubmed publisher
    ..This report summarizes the workshop discussions on key issues of the EPR effect and major gaps that need to be addressed to effectively advance nanoparticle-based drug delivery. ..
  9. Elinav E, Peer D. Harnessing nanomedicine for mucosal theranostics--a silver bullet at last?. ACS Nano. 2013;7:2883-90 pubmed publisher
    ..In this Perspective, we highlight issues related to emerging nanotechnologies designed particularly for treatment and disease management of IBD and discuss potential therapeutic target options with novel molecular imaging modalities. ..
  10. Taratula O, Dani R, Schumann C, Xu H, Wang A, Song H, et al. Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells. Int J Pharm. 2013;458:169-80 pubmed publisher
    ..Thus, the developed IONPs-based delivery system has high potential in the effective treatment of ovarian cancer by combinatorial approach. ..
  11. Master A, Livingston M, Sen Gupta A. Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release. 2013;168:88-102 pubmed publisher
    ..To this end, the nanomedicine approach provides a promising way towards enhanced control of photosensitizer biodistribution and tumor-..
  12. Master A, Malamas A, Solanki R, Clausen D, Eiseman J, Sen Gupta A. A cell-targeted photodynamic nanomedicine strategy for head and neck cancers. Mol Pharm. 2013;10:1988-97 pubmed publisher
    ..To this end, we report on a cell-targeted nanomedicine approach for the photosensitizer silicon phthalocyanine-4 (Pc 4), by packaging it within polymeric micelles ..
  13. Xu Q, Kambhampati S, Kannan R. Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol. 2013;20:26-37 pubmed publisher
    ..The application of nanotechnology in medicine is undergoing rapid progress, and the recent developments in nanomedicine-based therapeutic approaches may bring significant benefits to address the leading causes of blindness ..
  14. Sharma S, Rais A, Sandhu R, Nel W, Ebadi M. Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomedicine. 2013;8:1477-88 pubmed publisher
    ..This report highlights the clinical significance of MTs and their versatility as early, sensitive biomarkers in cell-based therapy and nanomedicine.
  15. Zhang Y, Wang L, Sun Y, Zhu Y, Zhong Z, Shi J, et al. Conjugation of dexamethasone to C60 for the design of an anti-inflammatory nanomedicine with reduced cellular apoptosis. ACS Appl Mater Interfaces. 2013;5:5291-7 pubmed publisher
    ..By conjugation of DEX with C60, we found that this nanomedicine retained the anti-inflammatory activity of DEX while reducing side effects in the animal model...
  16. Chen W, Xu X, Jia H, Lei Q, Luo G, Cheng S, et al. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials. 2013;34:8798-807 pubmed publisher
    ..The functionalized AuNPs with tumor-triggered drug release property can further improve the efficacy and reduce side effects significantly. ..
  17. Jin Y. Engineering plasmonic gold nanostructures and metamaterials for biosensing and nanomedicine. Adv Mater. 2012;24:5153-65 pubmed publisher
    The fields of biosensing and nanomedicine have recently witnessed an explosion of interest and progress in the design and study of plasmonic Au nanostructures (p-AuNSs) or metamaterials geared towards a broad range of biological and ..
  18. Bawa R. Regulating nanomedicine - can the FDA handle it?. Curr Drug Deliv. 2011;8:227-34 pubmed
    There is enormous excitement and expectation surrounding the multidisciplinary field of nanomedicine - the application of nanotechnology to healthcare - which is already influencing the pharmaceutical industry...
  19. Paszko E, Ehrhardt C, Senge M, Kelleher D, Reynolds J. Nanodrug applications in photodynamic therapy. Photodiagnosis Photodyn Ther. 2011;8:14-29 pubmed publisher
    ..This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. ..
  20. Rejiba S, Reddy L, Bigand C, Parmentier C, Couvreur P, Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine. 2011;7:841-9 pubmed publisher
    ..To overcome the above drawbacks we designed a novel nanomedicine strategy for Gem nanoparticle (NP) formulation based on squalene conjugation...
  21. Blanco E, Hsiao A, Mann A, Landry M, Meric Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 2011;102:1247-52 pubmed publisher
    ..b>Nanomedicine represents an innovative field with immense potential for improving cancer treatment, having ushered in several ..
  22. Al Jamal W, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44:1094-104 pubmed publisher
    ..Such hybrid structures could offer diagnostic and therapeutic combinations suitable for biomedical and even clinical applications. ..
  23. Kunjachan S, Błauz A, Möckel D, Theek B, Kiessling F, Etrych T, et al. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur J Pharm Sci. 2012;45:421-8 pubmed publisher
    ..These findings indicate that the ability of classical nanomedicines to overcome cellular MDR should not be overestimated. ..
  24. Nakamura T, Akita H, Yamada Y, Hatakeyama H, Harashima H. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc Chem Res. 2012;45:1113-21 pubmed publisher
    ..Some of these strategies will soon be tested in the clinic. ..
  25. Wang M, Gartel A. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther. 2011;10:2287-97 pubmed publisher
    ..Our data suggest that the thiazole antibiotic/proteasome inhibitor thiostrepton, when formulated into nanoparticles, may be highly suited as a nanomedicine for treating human cancer.
  26. Popov A, Zvyagin A, Lademann J, Roberts M, Sanchez W, Priezzhev A, et al. Designing inorganic light-protective skin nanotechnology products. J Biomed Nanotechnol. 2010;6:432-51 pubmed
    ..Particle penetration into skin is also an important issue addressed in this review due to possible adverse effects associated with interaction between nanoparticles and skin living cells. ..
  27. Anilkumar P, Lu F, Cao L, Luo P, Liu J, Sahu S, et al. Fullerenes for applications in biology and medicine. Curr Med Chem. 2011;18:2045-59 pubmed
    ..Also discussed are some other potential medically relevant applications of fullerenes, such as their serving as potent agents in photodynamic therapy and magnetic imaging. ..
  28. Gupta A. Nanomedicine approaches in vascular disease: a review. Nanomedicine. 2011;7:763-79 pubmed publisher
    b>Nanomedicine approaches have revolutionized the treatment of cancer and vascular diseases, where the limitations of rapid nonspecific clearance, poor biodistribution and harmful side effects associated with direct systemic drug ..
  29. Yoo D, Lee J, Shin T, Cheon J. Theranostic magnetic nanoparticles. Acc Chem Res. 2011;44:863-74 pubmed publisher
    ..The wide range of accessible features of magnetic nanoparticles underscores their potential as the most promising platform material available for theranostics. ..
  30. Daum N, Tscheka C, Neumeyer A, Schneider M. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4:52-65 pubmed publisher
    ..Therefore, the interaction pattern between nonspherical particulate materials and biological systems as well as the production processes are highlighted. ..
  31. Janowski M, Bulte J, Walczak P. Personalized nanomedicine advancements for stem cell tracking. Adv Drug Deliv Rev. 2012;64:1488-507 pubmed publisher
    ..The diversity of nanomaterials has revolutionized personalized nanomedicine and enables individualized tailoring of stem cell labeling materials for the specific needs of each patient...
  32. Khandare J, Calderon M, Dagia N, Haag R. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem Soc Rev. 2012;41:2824-48 pubmed publisher
    ..Advanced forms of nanomedicine have been synthesized for better pharmacokinetics to obtain higher efficacy, less systemic toxicity, and better ..
  33. Yang X, Hong H, Grailer J, Rowland I, Javadi A, Hurley S, et al. cRGD-functionalized, DOX-conjugated, and ??Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011;32:4151-60 pubmed publisher
    ..Thus, these SPIO nanocarriers demonstrated promising properties for combined targeted anticancer drug delivery and PET/MRI dual-modality imaging of tumors. ..
  34. Rodríguez Luccioni H, Latorre Esteves M, Méndez Vega J, Soto O, Rodriguez A, Rinaldi C, et al. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int J Nanomedicine. 2011;6:373-80 pubmed publisher
    ..The results presented here suggest that MFH most likely induces apoptosis in both cell types. When compared with HWH, MFH produced a significant reduction in cell viability, and these effects appear to be cell-type related. ..
  35. Kim K, Khang G, Lee D. Application of nanomedicine in cardiovascular diseases and stroke. Curr Pharm Des. 2011;17:1825-33 pubmed
    b>Nanomedicine is using nanotechnology in the medical application, which could range from medical use of nanomaterials in drug delivery and bio-imaging to development of nano-scale devices and sensors for diagnosis and therapy...
  36. Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res. 2011;44:999-1008 pubmed publisher
    ..By engineering the constituent block copolymers to produce polymeric micelles that integrate multiple smart functionalities, we and other researchers are developing nanodevices with favorable clinical properties. ..
  37. Lee J, Lee N, Kim T, Kim J, Hyeon T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res. 2011;44:893-902 pubmed publisher
    ..With innumerable combinations of imaging modalities and drug delivery available within these vehicles, multifunctional nanocomposite nanoparticles provide new opportunities for clinical diagnostics and therapeutics. ..
  38. Tsai hsuan Ku S. Forming interdisciplinary expertise: one organization's journey on the road to translational nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4:366-77 pubmed publisher
    ..provides a sociological account of how researchers of different disciplines become experts in translational nanomedicine. Using a case study of the Nanotechnology Characterization Laboratory (NCL) at the National Cancer Institute (..
  39. He Q, Ma M, Wei C, Shi J. Mesoporous carbon@silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging. Biomaterials. 2012;33:4392-402 pubmed publisher
  40. Lee D, Koo H, Sun I, Ryu J, Kim K, Kwon I. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012;41:2656-72 pubmed publisher
    b>Nanomedicine is the biomedical application of nanoscale materials for diagnosis and therapy of disease...
  41. Szelenyi I. Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases. Inflamm Res. 2012;61:1-9 pubmed publisher
    b>Nanomedicine, although in a nascent stage of development at present, is already a reality. Several pharmaceutical products using this modern technology are already on the market...
  42. Moghimi S, Wibroe P, Helvig S, Farhangrazi Z, Hunter A. Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. Adv Drug Deliv Rev. 2012;64:1385-93 pubmed publisher
    ..Although nanomedicine-mediated triggering of complement activation has been suggested to be a significant contributing factor to ..
  43. Xue X, Liang X. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer. 2012;31:100-9 pubmed publisher
    ..In this review, we discuss the mechanisms of drug efflux-mediated resistance and the application of multiple nanoparticle-based platforms to overcome chemoresistance and improve therapeutic outcome. ..
  44. Koppers Lalic D, Hogenboom M, Middeldorp J, Pegtel D. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv Drug Deliv Rev. 2013;65:348-56 pubmed publisher
    ..We discuss recent discoveries in exosome biogenesis their physical properties, targeting and delivery strategies and how the knowledge of exosome production in virus infected cells could propel their entry into clinical settings. ..
  45. Lehner R, Wang X, Wolf M, Hunziker P. Designing switchable nanosystems for medical application. J Control Release. 2012;161:307-16 pubmed publisher
    ..has had a major impact on preclinical development in medicine, shaping the emerging scientific field of nanomedicine. Diverse nanomaterial platforms have been introduced as a carrier systems for the delivery of a variety of ..
  46. Duarte I. Following dynamic biological processes through NMR-based metabonomics: a new tool in nanomedicine?. J Control Release. 2011;153:34-9 pubmed publisher
    ..In the field of nanotoxicology and nanomedicine, however, the potential unique benefits of applying metabonomics are only starting to be realised...
  47. Lammers T, Aime S, Hennink W, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44:1029-38 pubmed publisher
    b>Nanomedicine formulations aim to improve the biodistribution and the target site accumulation of systemically administered (chemo)therapeutic agents...
  48. Zhang X, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad O. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012;64:1363-84 pubmed publisher
  49. Maojo V, Fritts M, De La Iglesia D, Cachau R, Garcia Remesal M, Mitchell J, et al. Nanoinformatics: a new area of research in nanomedicine. Int J Nanomedicine. 2012;7:3867-90 pubmed publisher
    ..We suggest that nanoinformatics could accelerate research and development in nanomedicine, as has occurred in the past in other fields...
  50. Marsh J, Hu G, Scott M, Zhang H, Goette M, Gaffney P, et al. A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond). 2011;6:605-15 pubmed publisher
    To develop a fibrin-specific urokinase nanomedicine thrombolytic agent...
  51. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24:1504-34 pubmed publisher
    ..We conclude with our personal perspectives on the directions in which future work in this field might be focused. ..
  52. Tassa C, Shaw S, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44:842-52 pubmed publisher
    ..Finally, the targeted delivery of a photodynamic therapy agent as part of a theranostic nanoparticle successfully increased local cell toxicity and minimized systemic side effects. ..
  53. Binsalamah Z, Paul A, Prakash S, Shum Tim D. Nanomedicine in cardiovascular therapy: recent advancements. Expert Rev Cardiovasc Ther. 2012;10:805-15 pubmed publisher
    ..b>Nanomedicine has emerged as a potential strategy in dealing with these obstacles...